Amgen Inc. with price, financials, news flow, and insider context in one page.
Amgen Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where AMGN sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
This page is structured for research context, not a trade call. It gives you a clean read on where AMGN sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 8.62B | 1.82B | 1.48B |
| Q4 2025 | 9.87B | 1.33B | 961M |
| Q3 2025 | 9.56B | 3.22B | 4.25B |
| Q2 2025 | 9.18B | 1.43B | 1.91B |
This is Goldman's second downward revision in a week, which gives the cuts additional weight as a directional signal rather than a knee-jerk reaction. The bring-forward of Persian Gulf export norma...
On Monday, the Dow Jones Industrial Average climbed to new intraday and closing records on a potential deal between the U.S. and Iran.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Amgen Inc. (AMGN) — questions investors ask
What is the current stock price of Amgen Inc. (AMGN)?
Amgen Inc. (AMGN) is trading at $350.53, down 1.31% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Amgen Inc.'s market capitalization?
Amgen Inc. has a market capitalization of about 189.18B, derived from the latest share price and shares outstanding.
When is Amgen Inc.'s next earnings date?
Amgen Inc. is next expected to report earnings on Aug 4, 2026. The AMGN earnings page tracks the estimate and reporting history.
What is Amgen Inc.'s P/E ratio?
Amgen Inc. trades at a forward price-to-earnings ratio of 14.93 — one measure of how the market is pricing its future earnings.
What is AMGN's 52-week trading range?
Over the past 52 weeks, AMGN has traded between $267.83 and $391.29.
What sector is Amgen Inc. in?
Amgen Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does Amgen Inc. pay a dividend?
Amgen Inc. currently carries a dividend yield of about 100.0%.
What is the analyst price target for AMGN?
The mean analyst price target for AMGN is $352.50, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This AMGN page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.